{
  "extraction_metadata": {
    "timestamp": "2025-10-01T10:58:51.011220",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to progression of the tumor, time to deterioration, intraoperative complications, mortality, morbidity, adverse events, neurotoxicity, EORTC QLQ-C30, EQ-5D-5L",
      "ChunksUsed": 12,
      "ContextTokens": 2893
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, portal vein thrombosis, recurrence, delay of recurrence, adverse events (general)",
      "ChunksUsed": 12,
      "ContextTokens": 2963
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to progression of the tumor, time to deterioration, intraoperative complications, mortality, morbidity, adverse events, neurotoxicity",
      "ChunksUsed": 12,
      "ContextTokens": 2893
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "long-term survival, perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, recurrence, quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2057
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, median survival, prognosis (BCLC staging system), adverse events, long-term treatment-related complications",
      "ChunksUsed": 12,
      "ContextTokens": 2639
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "bleeding, tumour seeding, side-effects (biopsy-related), diagnosis (multiphasic CT, MRI, CT and MRI Liver Imaging Reporting and Data System (LI-RADS) v2018, contrast-enhanced ultrasound), pathological examination, immunohistochemistry markers (for diagnosis, prognosis, subtypes), genetic tests (for metabolic diseases), molecular classification (by specific mutations), surveillance (abdominal ultrasound or multiphase cross-sectional imaging every 6 months, with or without alpha-fetoprotein evaluation)",
      "ChunksUsed": 11,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "time-to-progression, toxicity, overall survival, response rates (RECIST criteria), adverse events, diarrhoea, fatigue, nausea, neutropenia, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 12,
      "ContextTokens": 3575
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "",
      "Error": "Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4.1 in organization org-qjlBCLCPywLruyzWD3MengrF on tokens per min (TPM): Limit 30000, Used 25845, Requested 4217. Please try again in 124ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "ChunksUsed": 12,
      "ContextTokens": 3023
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, tumour response rate, adverse events, adverse events (Grade â‰¥ 3), quality of life, overall quality of life (measured with a validated and reliable instrument), early detection of local recurrence, early detection of de novo tumor, distress (physical and psychological complaints), physical complaints, psychosocial complaints, emotional complaints, social complaints, spiritual complaints, burden of disease",
      "ChunksUsed": 12,
      "ContextTokens": 2916
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "response rates (RECIST criteria), response rates (mRECIST), response rates (RECIS systems), overall survival, perioperative mortality, adverse events, progression, time to progression, completeness of ablation (multiphase computed tomography with contrast), completeness of ablation (magnetic resonance imaging with contrast), effectiveness of ablation (magnetic resonance imaging), effectiveness of ablation (multiphase computed tomography), bridging therapy benefit, reduction of progression, histological parameters, immunohistochemical confirmation of hepatocytic origin, genetic diagnosis, undesirable effects, quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2703
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "EORTC QLQ-C30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, survival, quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 2045
    }
  }
}